Condition
Nummular Eczema
Total Trials
6
Recruiting
0
Active
2
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
Termination Rate
0.0%
0 terminated out of 6 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
33%
2 trials in Phase 3/4
Results Transparency
50%
1 of 2 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
5Total
P 2 (3)
P 3 (1)
P 4 (1)
Trial Status
Completed2
Active Not Recruiting2
Not Yet Recruiting1
Unknown1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (6)
Showing 6 of 6 trials
NCT07542483Phase 3Not Yet RecruitingPrimary
A Study of Lebrikizumab in Adults With Nummular Eczema
NCT04600362Phase 2Active Not RecruitingPrimary
Study of Dupilumab to Demonstrate Efficacy in Subjects With Nummular Eczema
NCT06994520Phase 2Active Not Recruiting
Efficacy of Topical Cannabidiol for Eczema
NCT03160248Phase 2CompletedPrimary
An Investigator-initiated Study of Apremilast to Demonstrate Efficacy Nummular Eczema
NCT03630198Phase 4Completed
Pain Outcomes Following Intralesional Corticosteroid Injections
NCT01311986Unknown
Chemokine Expression in Nummular Dermatitis and Atopic Dermatitis
Showing all 6 trials